Matches in Wikidata for { <http://www.wikidata.org/entity/Q90360116> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q90360116 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90360116 description "scientific article published on 01 June 2018" @default.
- Q90360116 description "wetenschappelijk artikel" @default.
- Q90360116 description "наукова стаття, опублікована в червні 2018" @default.
- Q90360116 name "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 name "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 type Item @default.
- Q90360116 label "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 label "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 prefLabel "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 prefLabel "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 P1433 Q90360116-7A159AA7-BA37-44C3-A2A2-FCD81217FD70 @default.
- Q90360116 P1476 Q90360116-2E86F689-BA65-42BD-B8B1-31011CC57E3A @default.
- Q90360116 P2093 Q90360116-2005DDC7-FB5B-4353-A07B-B4E9195FBB38 @default.
- Q90360116 P2093 Q90360116-2BA36895-8717-4E30-A933-C70162FC8B12 @default.
- Q90360116 P2093 Q90360116-424CD677-C8EE-4E63-8FF6-1556CCA35779 @default.
- Q90360116 P2093 Q90360116-437F992B-76C2-4054-96D4-2CCDB03A0EF6 @default.
- Q90360116 P2093 Q90360116-472AFE02-29E3-45E5-BD1E-3FD3F0E24070 @default.
- Q90360116 P2093 Q90360116-60F1470C-44F9-4484-A0EB-93A5663F7805 @default.
- Q90360116 P2093 Q90360116-6EAEDD7B-E147-4C39-B2F1-8E21A4A3D52A @default.
- Q90360116 P2093 Q90360116-758B895E-5EB2-457D-8EDA-82B5ECDDFC1D @default.
- Q90360116 P2093 Q90360116-A5DE4B2B-C594-4ABF-9066-1193DBC6E860 @default.
- Q90360116 P2093 Q90360116-C6418E57-A1EF-4610-B365-D9A68431C835 @default.
- Q90360116 P304 Q90360116-74B4A7DB-6D17-456A-96AF-FCDBAC1254BC @default.
- Q90360116 P31 Q90360116-E9818E7E-E6C7-4494-9B86-B6768AEC2773 @default.
- Q90360116 P356 Q90360116-4CE05F60-8022-47AC-8FEB-10FD76DCD7A2 @default.
- Q90360116 P478 Q90360116-E3447B35-16C6-4C97-9F22-D4EA70208DA8 @default.
- Q90360116 P577 Q90360116-F670162E-1D41-4971-AE98-08AE1269EB83 @default.
- Q90360116 P356 MDY150.018 @default.
- Q90360116 P1433 Q326122 @default.
- Q90360116 P1476 "RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]" @default.
- Q90360116 P2093 "A Nazarian" @default.
- Q90360116 P2093 "A Ocean" @default.
- Q90360116 P2093 "B Smith" @default.
- Q90360116 P2093 "D Wolf" @default.
- Q90360116 P2093 "J Thomas" @default.
- Q90360116 P2093 "L Gazda" @default.
- Q90360116 P2093 "N Berman" @default.
- Q90360116 P2093 "S Sureshbabu" @default.
- Q90360116 P2093 "T Fahey" @default.
- Q90360116 P2093 "Z Andrada" @default.
- Q90360116 P304 "v98" @default.
- Q90360116 P31 Q13442814 @default.
- Q90360116 P356 "10.1093/ANNONC/MDY150.018" @default.
- Q90360116 P478 "29 Suppl 5" @default.
- Q90360116 P577 "2018-06-01T00:00:00Z" @default.